{
    "nct_id": "NCT03412747",
    "official_title": "A Phase 3, Multicenter, Randomized, Double-Blind Study With an Active-Controlled Initial Treatment Period Followed by a Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis",
    "inclusion_criteria": "* Must be at least 18 years of age\n* Chronic plaque PSO for at least 6 months prior to the Screening Visit\n* Psoriasis Area Severity Index (PASI) >=12 and body surface area (BSA) affected by PSO >=10% and Investigator's Global Assessment (IGA) score >=3 on a 5-point scale\n* Subject is a candidate for systemic PSO therapy and/or phototherapy\n* Female subject of child bearing potential must be willing to use highly effective method of contraception\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Subject has a known hypersensitivity to any excipients of bimekizumab or adalimumab\n* Subject has an active infection (except common cold), a serious infection, or a history of opportunistic or recurrent chronic infections\n* Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection\n* Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection\n* Subject has any other condition, including medical or psychiatric, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in the study\n* Subject has had previous exposure to adalimumab\n* Presence of active suicidal ideation or positive suicide behavior\n* Presence of moderately severe major depression or severe major depression\n* Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer",
    "miscellaneous_criteria": ""
}